UBS AG has reiterated its "Buy" rating for Merck KGaA, with a target price of €190, following the company's recent capital market day.

Analyst Matthew Weston remains confident in the stock's attractive valuation and growth potential.

Merck shares are currently trading at €159.85 on the XETRA exchange, experiencing a slight decline of 1.3%. This indicates an upside potential of approximately 18.86% relative to UBS's target.

Since the beginning of 2024, Merck's share price has increased by 12.6%, reflecting positive market sentiment.

Investors are eagerly awaiting Merck's Q3 2024 results, which are scheduled to be released on November 14, 2024.

The trading volume for Merck shares in the XETRA session reached 15,353, indicating active market participation.